Jubilant Life Sciences Ltd ended at Rs. 367.3, up by Rs. 25.4 or 7.43% from its previous closing of Rs. 341.9 on the BSE. The company reported 23% rise in consolidated net profit at Rs.162 crore for the quarter ended June 30, 2016 as compared to Rs.132 crore for the quarter ended June 30, 2015.
Total Income has decreased from Rs.1449.5 crore for the quarter ended June 30, 2015 to Rs.1423.82 cr for the quarter ended June 30, 2016.
Commenting on the Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said: “We have started the Year FY 2017 on a positive note delivering strong performance in Pharmaceuticals segment which contributed about 70% of the company’s operating profit. We are glad to state that our company has built a robust long term sustainable business model with the growth engine of Pharmaceuticals and Drug Discovery Solutions segments. By creating focussed management teams for all the three segments of businesses, we are able to clearly define strategic initiatives with the right mix of capital allocation. We believe that the company will continue to deliver better performance going forward given the robust product pipeline in place.”
The scrip opened at Rs. 355 and touched a high and low of Rs. 380.8 and Rs. 353.5 respectively. A total of 5110433(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 5446.47 crore.
The BSE group ‘A’ stock of face value Rs. 1 touched a 52 week high of Rs. 455 on 07-Dec-2015 and a 52 week low of Rs. 261 on 08-Sep-2015. Last one week high and low of the scrip stood at Rs. 348.45 and Rs. 315.1 respectively.
The promoters holding in the company stood at 54.02 % while Institutions and Non-Institutions held 26.82 % and 16.71 % respectively.
The stock traded above its 200 DMA.